Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Anticitrullinated Protein Antibody, But Not Its Titer, Is a Predictor of Radiographic Progression and Disease Activity in Rheumatoid Arthritis

KAZUKO SHIOZAWA, YOSHIKO KAWASAKI, TAKASHI YAMANE, RYOSUKE YOSHIHARA, YASUSHI TANAKA, KENICHI UTO and SHUNICHI SHIOZAWA
The Journal of Rheumatology April 2012, 39 (4) 694-700; DOI: https://doi.org/10.3899/jrheum.111152
KAZUKO SHIOZAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIKO KAWASAKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI YAMANE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOSUKE YOSHIHARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI TANAKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENICHI UTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHUNICHI SHIOZAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shiozawa@beppu.kyushu-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To study the contribution of anticitrullinated protein antibody (ACPA), and especially of its titer, to radiographic progression and disease activity in rheumatoid arthritis (RA).

Methods. Patients with RA (n = 396) who attended a Japanese clinic within 2 years after disease onset were divided into the following groups according to second-generation (ACPA-2) ACPA titer on their first visit: negative (0–4.4 U/ml; n = 115), low-positive (4.5–121 U/ml; n = 141), and high-positive (> 121 U/ml; n = 140). The ACPA-2-positive groups were further subdivided into lowest (4.5–32 U/ml), low (33–121 U/ml), high (122–277 U/ml), and highest (> 278 U/ml) quartiles. All patients were treated with disease-modifying antirheumatic drugs (DMARD) including methotrexate, but not biologics. Subsequent radiographic progression and disease activity for 2 years were prospectively evaluated using the van der Heijde-modified Sharp score (SHS) and 28-joint Disease Activity Score (DAS28).

Results. After treatment with DMARD, the disease activity (including number of swollen joints, number of tender joints, duration of morning stiffness, DAS28-erythrocyte sedimentation rate, and DAS28-C-reactive protein) was significantly decreased in all patient groups. Disease activity and radiographic progression as revealed by the change in SHS remained relatively higher in the ACPA-2 low- and high-positive groups as compared with the ACPA-2-negative group. The relationship between the titer of ACPA-2 at baseline and subsequent radiographic progression was not exactly linear, and the extent of disease activity or radiographic progression was similar between ACPA-2 low- and high-positive groups and also between ACPA-2 lowest- and highest-positive quartile groups. The results were demonstrable in cumulative SHS probability plots, and also repeatable in seronegative patients, which indicated that the titer of ACPA-2 is not a predictor of disease activity or radiographic progression in RA, and ACPA-2-negative patients, especially those with < 3 U/ml, showed minimal radiographic progression.

Conclusion. Presence of ACPA-2, but not its titer, at baseline is a predictor of radiographic progression or disease activity, where radiographic progression is minimal in ACPA-2-negative patients.

Key Indexing Terms:
  • RHEUMATOID ARTHRITIS
  • ANTICITRULLINATED PROTEIN ANTIBODIES
  • DISEASE ACTIVITY
  • RADIOGRAPHIC PROGRESSION

Anticitrullinated protein antibodies (ACPA) hold promise for earlier and more accurate diagnosis of rheumatoid arthritis (RA) and are expected to improve prognostic information in RA1,2,3. Studies have shown that the presence of ACPA predicts a greater radiographic progression4,5,6,7,8,9,10,11,12,13 and possibly a less favorable disease course13,14,15 and consequently, ACPA and rheumatoid factor (RF) have been incorporated into recent European League Against Rheumatism/American College of Rheumatology (ACR) classification criteria16. However, studies to date suggest that clinical features of RA, including distribution of affected joints, swollen joints, bone erosions, and joint space narrowing13, or the remission rates for a relatively longer 3–5-year period17 were similar between the patients with and those without ACPA. One study also shows that the titer of ACPA predicts the disease activity of male patients only18. Another study shows that the extent of radiographic progression in the ACPA-negative patients may be comparable to those of ACPA-positive patients19. Thus, the attribute of ACPA in relation to radiographic progression and/or disease activity remains unclear in RA12,20,21,22,23.

We have studied whether the titer of ACPA can be a predictor of radiographic progression and/or disease activity in Japanese patients with RA (n = 396) who visited our hospital within 2 years after onset to clarify the clinical characteristics of ACPA in relation to the prognosis, i.e., disease activity and radiographic progression.

MATERIALS AND METHODS

Serum second-generation ACPA (ACPA-2) was measured in 396 patients with RA on their first visit to the Konan Kakogawa Hospital between April 2003 and March 2006. Only the patients who visited within 2 years after disease onset and were found to fulfill the ACR diagnostic criteria24 in later disease course were included in the study. We used an ACPA-2 assay widely used in Japan3. Its performance has been proved to be comparable to the third-generation ELISA kits2. The patients were treated mostly with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARD) and/or daily prednisolone ≤ 5 mg (Table 1). Patients were followed prospectively for 2 years. Patients treated with anti-tumor necrosis factor-α biological agents were not included in our study because the use of biologics was not common between 2003 and 2006 in Japan. The patients were divided according to ACPA-2 titer on their first visit (baseline) into a negative group (0–4.4 U/ml; n = 115) and low-positive (4.5–121 U/ml; n = 141) and high-positive (> 121 U/ml; n = 140) groups. The low- and high-positive groups were divided by referring to the median value, 121 U/ml. The ACPA-2-positive groups were further subdivided into lowest (4.5–32 U/ml; n = 70), low (33–121 U/ml; n = 71), high (122–277 U/ml; n = 70), and highest (> 278 U/m; n = 70) positive quartiles. Lowest- and highest-positive quartile groups were then compared. The clinical features and disease activities were assessed using disease activity scores including a 28-joint Disease Activity Score (DAS28)-erythrocyte sedimentation rate (ESR) [DAS28-ESR (3)] and DAS28-C-reactive protein (CRP) [DAS28-CRP (3)], laboratory measures of ESR, rheumatoid factor (RF), CRP, or matrix metalloproteinase 3 (MMP-3), and hand radiographic evaluation performed using van der Heijde-modified Sharp score (SHS), with a range of 0–306 (narrowing + erosion)25, and expressed as annual change from baseline between 0 and 48 weeks. To evaluate the independence of ACPA as a predictor of radiographic progression, we also identified RF-negative patients (n = 127) and assessed their radiographs.

View this table:
  • View inline
  • View popup
Table 1.

Baseline profile of patients with rheumatoid arthritis.

Statistical analyses were performed using the MedCalc system (MedCalc Software bvba, Mariakerke, Belgium). Data were expressed as the mean ± SD or median with interquartile range. All statistical tests were 2-sided and were performed at an α level of 0.05. Differences between groups were assessed using the parametric Student’s t-test or 1-way ANOVA. When distribution of the data was skewed, differences between groups were assessed using the nonparametric Mann-Whitney U test or the Kruskal-Wallis test. Categorical variables were assessed using chi-square test.

RESULTS

We divided patients with RA into 3 groups according to the titer of ACPA at baseline: negative (0–4.4 U/ml), low-positive (4.5–121 U/ml), and high-positive (> 121 U/ml). We found that RF and SHS at baseline were relatively higher in the ACPA low-positive and high-positive groups as compared with the negative group (Table 1), suggesting that joint destruction might have been faster in the ACPA-2-positive groups in the period before visiting the hospital, because the patients’ disease durations were similar.

It was noted that the relationship between the titer of ACPA-2 at baseline and subsequent radiographic progression was more or less variable and not exactly linear; however, radiographic progression of ACPA-2-negative patients, especially those with < 3 U/ml, was minimal (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Relationship between the titer of ACPA-2 and the annual change in van der Heijde-modified Sharp score (SHS) of hands from baseline. Note that radiographic progression in ACPA-2-negative patients, especially those with < 3 U/ml, was minimal.

All patients were treated with DMARD including MTX, but not biologics (Table 2). After treatment, the data for ESR, CRP and MMP-3 in sera, number of swollen joints, number of tender joints, duration of morning stiffness, DAS28-ESR (3), and DAS28-CRP (3) were all significantly improved in the ACPA-2-negative group (Table 2). It was noted that CRP, number of swollen joints, number of tender joints, duration of morning stiffness, DAS28-ESR (3), and DAS28-CRP (3) remained relatively higher in the ACPA-2 low-positive and high-positive groups (Table 2), indicating that the patients with negative ACPA-2 had less active disease. Thus, while the presence or absence of ACPA-2 at baseline predicts disease outcome of RA, the titer of ACPA-2 at baseline appeared not to predict disease activity significantly.

View this table:
  • View inline
  • View popup
Table 2.

Profile of patients with RA at 2-year followup. Mean ± SD or median (interquartile range) unless otherwise specified.

With regard to joint destruction, SHS was significantly increased in the ACPA-2 low-positive and high-positive groups after 2 years of treatment (Tables 1 and 2). However, the extent of annual change in SHS with regard to joint narrowing, erosion, and total score was similar between ACPA-2 low-positive and high-positive groups (Table 2). The change in SHS as a cumulative probability plot showed a marked difference between ACPA-2 low- and high-positive groups as compared with the ACPA-negative group (Figure 2). Importantly, there was no difference in the change in SHS between ACPA-2 low-positive and high-positive groups. It thus appears that absence of ACPA-2 at baseline predicts better joint prognosis, whereas the titer of ACPA-2 at baseline itself appears to be irrelevant to radiographic progression (Figure 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Cumulative probability plot shows annual change in van der Heijde-modified Sharp score (SHS) of hands from baseline, for ACPA-2 titer in all patients with rheumatoid arthritis (n = 396).

To confirm these findings, we compared ACPA-2 lowest-positive and highest-positive groups (Tables 3 and 4), with the patients grouped into lowest and highest quartiles. It was again noted that disease activity and radiographic progression were similar between ACPA-2 lowest and highest groups (Tables 3 and 4, Figure 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Cumulative probability plot shows annual change in van der Heijde-modified Sharp score (SHS) of hands from baseline, for ACPA-2 titer in patients with the ACPA-2 lowest-positive quartile (4.5–32) and highest-positive quartile (> 278) in comparison to ACPA-2-negative (< 4.5) patients.

View this table:
  • View inline
  • View popup
Table 3.

Baseline profile of patients with RA, comparing lowest quartile to highest quartile. Data are mean ± SD or median (interquartile range) unless otherwise specified.

View this table:
  • View inline
  • View popup
Table 4.

Profile of patients with RA at 2-year followup, comparing lowest quartile to highest quartile. Data are mean ± SD or median (interquartile range) unless otherwise specified.

To verify whether ACPA-2 is a predictor of radiographic progression independent of RF, we identified 126 RF-negative patients and assessed their radiographic progression rate. We found that annual change in SHS from baseline was significantly higher in the ACPA-2 low-positive (n = 22) and high-positive (n = 19) groups as compared to the ACPA-2-negative group (n = 85), respectively: 9.9 ± 10.8 and 10.0 ± 11.2 versus 3.9 ± 8.3 (p = 0.01 and p = 0.018, respectively). The change in SHS as a cumulative probability plot for RF-negative patients is shown in Figure 4.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Cumulative probability plot shows annual change in van der Heijde-modified Sharp score (SHS) of hands from baseline, for ACPA-2 titer in patients who were negative for rheumatoid factor (n = 126).

DISCUSSION

The results show that presence of ACPA-2, but not its titer, at baseline is a predictor of radiographic progression and disease activity in RA. The difference in disease activity and radiographic progression between ACPA-2-negative and ACPA-2-positive patients was significant. It was noted that radiographic progression illustrated as a cumulative probability plot was significantly different (Figure 2).

The results showed that radiographic progression of ACPA-2-negative patients, especially those with < 3 U/ml, was minimal (Figure 1). To our knowledge, an exact comparison between the titer of ACPA at baseline and subsequent radiographic progression in a prospective fashion has been made for the first time in our study, and the result showed that the relationship between the titer of ACPA-2 at baseline and radiographic progression was variable and not exactly linear (Figure 1). While the patients who were positive for ACPA-2 had relatively active disease despite treatment with DMARD in this and previous studies26, we found that radiographic progression was not always faster in ACPA-positive patients: there are exceptions. This finding is compatible with the previous findings that the effect of ACPA on radiographic progression reaches statistically significant levels only after 3 to 64,7,10,19 or even 1020 years of study: thus, the quantitative contribution of ACPA-2 is not very significant.

As to why ACPA-2 at baseline fails to show an exact linear relationship with radiographic progression, an explanation could be as follows. Our previous study using the largest number of patients with very early onset of RA (67 patients < 3 months, 120 patients < 6 months out of 435 patients < 2 years from disease onset)3 showed that, while ACPA-2 alone was highly specific and accurately predicted future development of RA when measured very early, i.e., within 3 months after disease onset, such accuracy was gradually lost when measured beyond 6 months after onset, probably because factors other than ACPA also are associated with the pathogenesis of arthritis27,28,29. In our study, the disease duration was between 6 and 10 months (Table 1), and therefore it is reasonable that the titer of ACPA-2 did not correlate exactly with radiographic progression. Taking these findings together, we may conclude that radiographic progression is minimal when ACPA is negative; however, radiographic progression is not always faster when the titer of ACPA is high. Further, in our study, serum ACPA was measured more than twice in 41 of 115 ACPA-negative patients. The result showed that ACPA-2 was consistently negative in all 41 patients. Since studies show that serum ACPA decreases only slightly but statistically significantly after treatment15,30,31, the absence of ACPA-2 as determined any time during the disease course may be a reliable predictor of minimal radiographic progression in RA. In summary, therefore, the presence of ACPA-2, but not its titer, at baseline can be a predictor of radiographic progression or disease activity. In particular, we may conclude that radiographic progression is minimal in ACPA-2-negative patients, whereas it is not predictable whether radiographic progression is always faster in ACPA-2-positive patients.

Acknowledgment

We thank Takahiro Makishita, PhD, and Naoki Akamatsu, PhD, for critically reviewing the manuscript and helping in statistical evaluation of the results.

  • Accepted for publication November 22, 2011.

REFERENCES

  1. 1.↵
    1. Szodoray P,
    2. Szabo Z,
    3. Kapitany A,
    4. Gyetvai A,
    5. Lakos G,
    6. Szanto S,
    7. et al.
    Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010;9:140–3.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. van der Linden MP,
    2. van der Woude D,
    3. Ioan-Facsinay A,
    4. Levarht EW,
    5. Stoeken-Rijsbergen G,
    6. Huizinga TW,
    7. et al.
    Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009;60:2232–41.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Yamane T,
    2. Hashiramoto A,
    3. Tanaka Y,
    4. Tsumiyama K,
    5. Miura Y,
    6. Shiozawa K,
    7. et al.
    Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor. J Rheumatol 2008;35:414–20.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kroot EJ,
    2. de Jong BA,
    3. van Leeuwen MA,
    4. Swinkels H,
    5. van den Hoogen FH,
    6. van ‘t Hof M,
    7. et al.
    The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831–5.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Vencovsky J,
    2. Machacek S,
    3. Sedova L,
    4. Kafkova J,
    5. Gatterova J,
    6. Pesalova V,
    7. et al.
    Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427–30.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Forslind K,
    2. Ahlmen M,
    3. Eberhardt K,
    4. Hafstrom I,
    5. Svensson B; and
    6. for the BARFOT study group
    . Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CP). Ann Rheum Dis 2004;63:1090–5.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Meyer O,
    2. Labarre C,
    3. Dougados M,
    4. Goupille Ph,
    5. Cantagrel A,
    6. Dubois A,
    7. et al.
    Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120–6.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. De Rycke L,
    2. Peene I,
    3. Hoffman IE,
    4. Kruithof E,
    5. Union A,
    6. Meheus L,
    7. et al.
    Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587–93.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Nell VP,
    2. Machold KP,
    3. Stamm TA,
    4. Eberl G,
    5. Heinzl H,
    6. Uffmann M,
    7. et al.
    Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731–6.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Lindqvist E,
    2. Eberhardt K,
    3. Bendtzen K,
    4. Heinegard D,
    5. Saxne T
    . Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196–201.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Nell-Duxneuner V,
    2. Machold K,
    3. Stamm T,
    4. Eberl G,
    5. Heizl H,
    6. Hoefler E,
    7. et al.
    Autoantibody profiling in patients with very early rheumatoid arthritis: A follow-up study. Ann Rheum Dis 2010;69:169–74.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Nieto-Colonia AM,
    2. Santos WS,
    3. Keusseyan SP,
    4. Caldana W,
    5. Fernandes AR,
    6. Andrade LE
    . Antibodies to citrullinated peptides are not associated with the rate of joint destruction in patients with a well-established diagnosis of rheumatoid arthritis. Braz J Med Biol Res 2008;41:188–92.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. van der Helm-van Mil AH,
    2. Verpoort KN,
    3. Breeveld FC,
    4. Toes RE,
    5. Huizinga TW
    . Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949–58.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Kastbom A,
    2. Strandberg G,
    3. Lindroos A,
    4. Skogh T
    . Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085–9.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Ronnelid J,
    2. Wick MC,
    3. Lampa J,
    4. Lindblad S,
    5. Nordmark B,
    6. Klareskog L,
    7. et al.
    Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744–9.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Aletaha D,
    2. Neogi T,
    3. Silman A,
    4. Funovits J,
    5. Felson DT,
    6. Bingham CO 3rd.,
    7. et al.
    2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Gossec L,
    2. Dougados M,
    3. Goupille P,
    4. Cantagrel A,
    5. Sibilia J,
    6. Meyer O,
    7. et al.
    Prognostic factors for remission in early rheumatoid arthritis: A multiparameter prospective study. Ann Rheum Dis 2004;63:675–80.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Miriovsky BJ,
    2. Michaud K,
    3. Thiele GM,
    4. O’Dell JR,
    5. Cannon GW,
    6. Kerr G,
    7. et al.
    Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 2010;69:1292–7.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Meyer O,
    2. Nicaise-Roland P,
    3. dos Santos M,
    4. Labarre C,
    5. Dougados M,
    6. Goupille P,
    7. et al.
    Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006;8:R40.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Syversen SW,
    2. Gaarder PI,
    3. Goll GL,
    4. Odegard S,
    5. Haavardsholm EA,
    6. Mowinckel P,
    7. et al.
    High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212–7.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Quinn MA,
    2. Gough KS,
    3. Green MJ,
    4. Devlin J,
    5. Hensor EMA,
    6. Greenstein A,
    7. et al.
    Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2005;45:478–80.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Reneses S,
    2. Gonzalez-Escribano MF,
    3. Fernandez-Suarez A,
    4. Pestana L,
    5. Davila B,
    6. Wichmann I,
    7. et al.
    The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis. J Rheumatol 2009;36:1143–9.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Ursum J,
    2. Bos WH,
    3. van Dillen N,
    4. Dijkmans BA,
    5. van Schaardenburg D
    . Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: A cohort study. Arthritis Res Ther 2010;12:R8.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. van der Heijde D
    . How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261–3.
    OpenUrlPubMed
  26. 26.↵
    1. Farragher TM,
    2. Lunt M,
    3. Plant D,
    4. Bunn DK,
    5. Barton A,
    6. Symmons DP
    . Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res 2010;62:664–75.
    OpenUrlCrossRef
  27. 27.↵
    1. Aikawa Y,
    2. Morimoto K,
    3. Yamamoto T,
    4. Chaki H,
    5. Hashiramoto A,
    6. Narita H,
    7. et al.
    Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008;26:817–23.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Shiozawa S,
    2. Tsumiyama K
    . Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle 2009;8:1539–43.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Shiozawa S,
    2. Tsumiyama K,
    3. Yoshida K,
    4. Hashiramoto A
    . Pathogenesis of joint destruction in rheumatoid arthritis. Arch Immunol Ther Exp 2011;59:89–95.
    OpenUrlCrossRef
  30. 30.↵
    1. Alessandri C,
    2. Bombardieri M,
    3. Papa N,
    4. Cinquini M,
    5. Magrini L,
    6. Tincani A,
    7. et al.
    Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218–21.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Mikuls TR,
    2. O’Dell JR,
    3. Stoner JA,
    4. Parrish LA,
    5. Arend WP,
    6. Norris JM,
    7. et al.
    Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776–82.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 4
1 Apr 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anticitrullinated Protein Antibody, But Not Its Titer, Is a Predictor of Radiographic Progression and Disease Activity in Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anticitrullinated Protein Antibody, But Not Its Titer, Is a Predictor of Radiographic Progression and Disease Activity in Rheumatoid Arthritis
KAZUKO SHIOZAWA, YOSHIKO KAWASAKI, TAKASHI YAMANE, RYOSUKE YOSHIHARA, YASUSHI TANAKA, KENICHI UTO, SHUNICHI SHIOZAWA
The Journal of Rheumatology Apr 2012, 39 (4) 694-700; DOI: 10.3899/jrheum.111152

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Anticitrullinated Protein Antibody, But Not Its Titer, Is a Predictor of Radiographic Progression and Disease Activity in Rheumatoid Arthritis
KAZUKO SHIOZAWA, YOSHIKO KAWASAKI, TAKASHI YAMANE, RYOSUKE YOSHIHARA, YASUSHI TANAKA, KENICHI UTO, SHUNICHI SHIOZAWA
The Journal of Rheumatology Apr 2012, 39 (4) 694-700; DOI: 10.3899/jrheum.111152
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
  • Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
  • Clustering Patients With Gout Based on Comorbidities and Biomarkers: A Cross-Sectional Study
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire